ReviewCurrent allergy and asthma reports2021
Distinguishing Blau Syndrome from Systemic Sarcoidosis.
Review in Current allergy and asthma reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Off-label use of canakinumab in pediatric rheumatology and rare diseases.Frontiers in medicine · 2022Pooled it
- Blau syndrome initially presenting with hypercalcemia: a case report and literature review.Annals of pediatric endocrinology & metabolism · 2026Article
- Successful Treatment of Cutaneous Manifestations of Blau Syndrome with UVA-1 Phototherapy in a Paediatric Patient.Acta dermato-venereologica · 2026Article
- Inactivation of NF-κB and MAPKs confers the potent therapeutic effect of carboxyamidotriazole on Blau syndrome.Arthritis research & therapy · 2026Article
- Immunological analysis of Blau syndrome, a unique autoinflammatory state.Frontiers in immunology · 2026Review
- Differential Transcriptomic Features of Peripheral Blood Mononuclear Cells in Pulmonary Sarcoidosis with and Without Extrapulmonary Lesions in an East Asian Population.Biomedicines · 2025Article
- Concurrent uveitis in monozygotic twins in the context of systemic sarcoidosis.Journal of ophthalmic inflammation and infection · 2025Article
- Long-term prognosis of 47 pediatric patients with Blau syndrome in China.BMC pediatrics · 2025Article
- A framework for exclusion of alternative diagnoses in sarcoidosis.Journal of autoimmunity · 2024Review
- Sarcoidosis: a general overview.Advances in rheumatology (London, England) · 2024Review
- Diagnosis and Treatment of Uveitis in Children: A Summary of the Latest Data from a 5-Year Literature Review (2018-2023).Journal of clinical medicine · 2024Review
- Review
- Phenotype of Takayasu-like vasculitis and cardiopathy in patients with Blau syndrome.Clinical rheumatology · 2024Article
- Molecular Foundations of Inflammatory Diseases: Insights into Inflammation and Inflammasomes.Current issues in molecular biology · 2024Review
- Management of Blau syndrome: review and proposal of a treatment algorithm.European journal of pediatrics · 2024Review
- The Etiologic Landscape of Lymphoproliferation in Childhood: Proposal for a Diagnostic Approach Exploring from Infections to Inborn Errors of Immunity and Metabolic Diseases.Therapeutics and clinical risk management · 2024Review
- Uveitis Associated with Monogenic Autoinflammatory Syndromes in Children.Ocular immunology and inflammation · 2023Review
- Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis.Journal of ophthalmic inflammation and infection · 2023Review
- Case Report: Methotrexate and hydroxychloroquine in combination for the treatment of NOD2-mutation-associated Blau syndrome.Frontiers in immunology · 2023Article
- Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome.Pediatric rheumatology online journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThe purpose of this review is to provide a framework to distinguish Blau syndrome/Early Onset Sarcoidosis and Sarcoidosis clinically. We also discuss relevant differences in genetics, pathogenesis, and management of these diseases. RECENT
findingsBlau syndrome and Sarcoidosis share the characteristic histologic finding of noncaseating granulomas as well as some similar clinical characteristics; nevertheless, they are distinct entities with important differences between them. Blau syndrome and Early Onset Sarcoidosis are due to one of numerous possible gain-of-function mutations in NOD2, commonly presenting before age 5 with a triad of skin rash, arthritis, and uveitis. However, as more cases are reported, expanded clinical manifestations have been described. In systemic Sarcoidosis, there are numerous susceptibility genes that have been identified, and disease is thought to result from an environmental exposure in a genetically susceptible host. It most often presents with constitutional symptoms and pulmonary involvement and typically affects adolescents and adults. This paper reviews the similarities and differences between Blau syndrome and Sarcoidosis. We also discuss the importance of distinguishing between them, particularly with regard to prognosis and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.